US politicians criticise Pfizer-Allergan deal US politicians have condemned the Pfizer deal with Allergan as a tax dodge, bringing another round of hand-wringing in Washington over the corporate tax code. Business • 24 Nov 15
US politicians criticise Pfizer-Allergan deal US politicians have condemned the Pfizer deal with Allergan as a tax dodge, bringing another round of hand-wringing in Washington over the corporate tax code. Business • 24 Nov 15
Pfizer to buy Allergan in $160 billion deal Pfizer, the maker of Viagra and Lipitor, has struck a deal to buy Botox-maker Allergan in a transaction valued at about $160 billion, creating the world's biggest drugmaker. Business • 23 Nov 15
Pfizer to buy Allergan in $160 billion deal Pfizer, the maker of Viagra and Lipitor, has struck a deal to buy Botox-maker Allergan in a transaction valued at about $160 billion, creating the world's biggest drugmaker. Business • 23 Nov 15
US unveils new inversion rules The US Treasury Department has taken steps to clamp down on tax-avoiding "inversion" deals with new rules, though there was scarce evidence they would stop the proposed Pfizer-Allergan deal. Business • 20 Nov 15
US unveils new inversion rules The US Treasury Department has taken steps to clamp down on tax-avoiding "inversion" deals with new rules, though there was scarce evidence they would stop the proposed Pfizer-Allergan deal. Business • 20 Nov 15
Allergan says in 'friendly talks' with Pfizer Botox maker Allergan today said it was in preliminary, friendly talks with Pfizer on a potential merger, a deal that would create the world's largest drugmaker. Business • 29 Oct 15
Allergan says in 'friendly talks' with Pfizer Botox maker Allergan today said it was in preliminary, friendly talks with Pfizer on a potential merger, a deal that would create the world's largest drugmaker. Business • 29 Oct 15
Israel's Teva to buy Allergan for $40.5bn Israeli pharmaceutical giant Teva said that it was buying the generic drug business of Allergan for $40.5 billion, consolidating its position as a world leader in generics. Business • 27 Jul 15
Israel's Teva to buy Allergan for $40.5bn Israeli pharmaceutical giant Teva said that it was buying the generic drug business of Allergan for $40.5 billion, consolidating its position as a world leader in generics. Business • 27 Jul 15
Allergan agrees to Actavis deal for $66 billion Allergan has agreed to be bought by Actavis for $66 billion, putting an end to a hostile bid by activist investor William Ackman and Valeant Pharmaceuticals. Business • 17 Nov 14
Allergan agrees to Actavis deal for $66 billion Allergan has agreed to be bought by Actavis for $66 billion, putting an end to a hostile bid by activist investor William Ackman and Valeant Pharmaceuticals. Business • 17 Nov 14
Valeant begins exchange offer for Allergan Valeant Pharmaceuticals said it had begun an exchange offer for Botox maker Allergan, taking its hostile $50.8 billion bid directly to shareholders. Business • 19 Jun 14
Valeant begins exchange offer for Allergan Valeant Pharmaceuticals said it had begun an exchange offer for Botox maker Allergan, taking its hostile $50.8 billion bid directly to shareholders. Business • 19 Jun 14
Valeant injects cash into bid for Botox maker Valeant Pharmaceuticals International has raised the cash component of its unsolicited offer for Botox-maker Allergan. Business • 28 May 14
Valeant injects cash into bid for Botox maker Valeant Pharmaceuticals International has raised the cash component of its unsolicited offer for Botox-maker Allergan. Business • 28 May 14
Ackman and Valeant team up to bid for Allergan Activist investor William Ackman teamed up with Canada's Valeant Pharmaceuticals International to make a joint run at buying Allergan. Business • 22 Apr 14
Ackman and Valeant team up to bid for Allergan Activist investor William Ackman teamed up with Canada's Valeant Pharmaceuticals International to make a joint run at buying Allergan. Business • 22 Apr 14
